- Home
- PAC vs EXEL Comparison
PAC vs EXEL Comparison
Compare PAC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAC | EXEL |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 11.7B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | PAC | EXEL |
|---|---|---|
| Price | $232.72 | $41.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $270.00 | $46.45 |
| AVG Volume (30 Days) | 90.1K | ★ 2.7M |
| Earning Date | 04-27-2026 | 02-10-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $40.63 | $13.66 |
| Revenue Next Year | $10.68 | $13.73 |
| P/E Ratio | $27.29 | ★ $14.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $168.62 | $32.38 |
| 52 Week High | $300.41 | $48.74 |
Technical Indicators
Market Signals| Indicator | PAC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 44.19 |
| Support Level | $211.42 | $40.01 |
| Resistance Level | $239.33 | $44.15 |
| Average True Range (ATR) | 9.20 | 1.24 |
| MACD | -1.55 | -0.05 |
| Stochastic Oscillator | 19.83 | 33.27 |
Price Performance
Historical ComparisonAbout PAC Grupo Aeroportuario Del Pacifico
Grupo Aeroportuario del Pacifico SAB de CV is engaged in the construction, development, and operation of airports in Mexico. The company's segment includes Guadalajara; Tijuana; Puerto Vallarta; San Jose del Cabo; Montego Bay; Hermosillo; Guanajuato and Other Airports. It generates maximum revenue from the Guadalajara segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.